Octapharma USA, a US Army Medical Materiel Development Activity commercial partner, has received FDA emergency use authorization for octaplasLG Powder, a potentially lifesaving treatment option for blood replacement therapies in certain operational circumstances. The EUA authorizes military medical commands to procuring and administeri...
The US Army has cleared a new whole blood rapid test for traumatic brain injury assessment, allowing clinicians to obtain lab-quality results at the bedside in 15 minutes. This improvement enables faster decision-making and reduces unnecessary medical evacuations.
A groundbreaking clinical trial launched by the U.S. Army aims to find new treatments for post-traumatic stress disorder (PTSD) in military personnel and veterans. The trial will test multiple drug candidates and examine biological indicators to determine potential treatments.
The US Army Medical Materiel Development Activity has developed a shelf-stable treatment for snakebite envenoming that is safe, easy to use, and independent of snake species. Clinical trials are ongoing in the US and India, with pre-clinical studies suggesting its potential use worldwide.